CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) VP David Foehr sold 9,255 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total transaction of $224,433.75. Following the completion of the transaction, the vice president owned 34,144 shares of the company’s stock, valued at $827,992. This trade represents a 21.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
David Foehr also recently made the following trade(s):
- On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The stock was sold at an average price of $23.95, for a total transaction of $20,573.05.
- On Friday, August 21st, David Foehr sold 993 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $23,851.86.
CeriBell Stock Performance
CBLL opened at $23.63 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The company has a market capitalization of $906.92 million, a price-to-earnings ratio of -13.43 and a beta of 0.95. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $25.33. The business’s 50-day moving average price is $21.11 and its two-hundred day moving average price is $19.64.
Hedge Funds Weigh In On CeriBell
Hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its position in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after buying an additional 854 shares during the last quarter. Sei Investments Co. increased its holdings in shares of CeriBell by 2.3% during the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after acquiring an additional 1,125 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the period. Deutsche Bank AG raised its stake in CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after acquiring an additional 1,393 shares during the period. Finally, Strs Ohio acquired a new stake in CeriBell during the 1st quarter valued at $27,000.
Analyst Ratings Changes
CBLL has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research report on Friday. Weiss Ratings downgraded CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 28th. Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Canaccord Genuity Group raised their price target on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $29.00 price objective on shares of CeriBell in a research note on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.40.
Check Out Our Latest Research Report on CeriBell
About CeriBell
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
See Also
- Five stocks we like better than CeriBell
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
